Best Practices and Solutions in the New Inflammation Paradigm
Covance recently hosted a webinar “Best Practices and Solutions in the New Inflammation Paradigm,” where two Covance experts (Global Therapeutic Area Head for Inflammation Dr. Michael George and...
View ArticleStudy Links Selection of Preferred Central Lab to Investigator Satisfaction
Landmark study links overall clinical trial investigator satisfaction with sponsors’ choice of Central Laboratory. Recruiting productive and experienced clinical trial investigators is a critical...
View ArticleDried Blood Spot Technique Making a Comeback
In recent years there has been renewed interest in the Dried Blood Spot (DBS) technique for determining drug levels in blood samples. The advantages it offers – including less blood per sample, easier...
View ArticleIdentifying Challenges and Proposing Solutions in Conducting Alzheimer’s...
With Alzheimer’s disease increasing across the globe, the demand for preventative, disease-modifying, and curative treatments is mounting. However, there remain several obstacles, including a high...
View ArticleUnlocking Brain Tumor Biology: Covance’s Genomics Laboratory and the...
In March 2011, Covance’s Seattle-based Genomics Laboratory (CGL) collaborated with the Institute for Systems Biology (ISB), also based in Seattle, to collectively unravel the complex regulation of gene...
View ArticleWhy Some Sponsors are Considering Dedicated Resource Agreements
Many sponsor-CRO relationships are based upon one or more transactional agreements that are each focused on a specific project. Projects are offered by the sponsor and are generally bid upon by a...
View ArticlePartnering for Success in Personalized Medicine: Central Labs and Companion...
As the biopharmaceutical industry increasingly turns its focus to discovering and delivering targeted, personalized medications, the companion diagnostics field is rapidly advancing. By 2015, the...
View ArticleEnabling Go/No-Go Decisions in the Drug Development Process: Enrichment...
Study efficiency is critical in the competitive Phase I oncology environment where a large number of (NMEs) are all competing for the same medical resources. There is a growing trend to evaluate...
View ArticleOncology Clinical Trials: Patient Recruitment Challenges and Anatomic...
Cancer is a disease that affects all of us; we all know someone with cancer, or have been diagnosed ourselves. Total cancer deaths worldwide in 2008 were approximately 7.6 million – approximately 13%...
View ArticleInfographic: Central Laboratory Services Overview
Did you know that Covance is the worldwide leader in clinical trial central laboratory services? Did you know that we have the ability to ship out more than 20,000 customized kits, uniquely designed...
View ArticleBiotherapeutics and Immunogenicity Implications in Drug Development
In contrast to new chemical entities, biotherapeutic drugs are potentially immunogenic, and, in rare cases, treatment with such products can lead to severe and devastating illnesses in humans....
View ArticleManaging Drug Development Challenges for Inflammation Therapies
Incorporating technologies such as biomarkers into the development of inflammation therapies can improve the development and delivery of the right therapy, at the right dose, to the right patient....
View ArticleNovel Tissue Types for the Development of Genomic Biomarkers
Imagine a simple clinical test that can not only diagnose a disease, but that can also identify the exact, personal therapeutic regime to cure it. Not only that, imagine tests that can accurately...
View ArticleBiosimilars Development Demands Expertise Across All Phases of Development
This is an exciting time for biosimilars. Based on a recent MarketsandMarkets report, the global biosimilars market is expected to be worth $19.4 billion by 2014, growing at a CAGR of 89.1% from 2009...
View ArticlePerfect (Storm) Performance: How Covance Central Laboratory Services...
Day in and day out, you hold us to a high standard in managing your clinical trials’ logistics needs. The infrastructure that enables us to deliver greater than 99% sample receipt within stability...
View ArticleUnique Market Access Considerations for Small Biopharmas
All biopharmaceutical companies have at least three hurdles to leap before a new product can launch: safety, efficacy, and quality. Small biopharmas have an additional hurdle, however: market access...
View ArticleOncology Studies and the Shift to a Centralized Lab Approach
Last month I was interviewed by ClinicalLeader for an article about how the central laboratory approach, as opposed to the traditional, distributed model of clinical trial lab testing, is driving...
View ArticleAddressing Ever-Rising Cost in Conducting Clinical Trials [Infographic]
Updated: The infographic was replaced on 12-Feb. If you are a procurement or operations professional responsible for delivering successful clinical trials, you will be under constant pressure to keep...
View ArticleCovance Teamwork and Xcellerate® Delivers Oncology Study 1 Year Early
When a large multinational client asked Covance to conduct a Phase III trial on a promising new colorectal cancer drug, their rigorous patient selection criteria initially caused some concern. How long...
View ArticleBiomarker Development and Disease Pathology in Modern Healthcare
Effective drug development requires a thorough understanding of diseases, especially as we produce ever more targeted drugs. In addition, with the 65+ age group growing worldwide (estimated to reach...
View Article
More Pages to Explore .....